Denise Maria Dardano

Dr. Denise Maria Dardano


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
DDDenise Maria Dardano
Denise Maria Dardano
MSMaria Serra
Maria Serra
SUSara Ussia
Sara Ussia
GRGiovanna Ritorto
Giovanna Ritorto
CACarmen Altomare
Carmen Altomare
RMRoberta Macrì
Roberta Macrì
The gut microbiota’s (GM) regulation of inflammation and oxidative stress is supported by existing evidence, and its dysregulation relates to brain disease. Indeed, probiotics and prebiotics have been shown to improve cognitive function. This is associated with a stronger gut and blood–brain barrier and less gut inflammation. Oligofructose-enriched inulin alters the GM, reduces body fat, and lowers interleukin-6 (IL-6) in obese patients. Moreover, by increasing glutathione (GSH), the ketogenic diet (KD) prevents seizures and also benefits the intestinal short-chain fatty acid (SCFA) profile. Given the evidence on managing epileptic conditions, the aim of this review is to assess how changing the gut microbiota (GM) can be a therapeutic method for preventing neurodegenerative dysfunctions associated with epileptic seizure onset and progression, with a focus on innovative supplement strategies, including endogenous and exogenous antioxidants, nutrition, and new phyto-therapies. Indeed, though drugs are the main treatment for epilepsy, the KD and other supplements are increasingly being considered. These compounds affect neuronal excitability, neurotransmitter release, and neuroinflammation, thus providing an anticonvulsant effect. Specifically, the KD prevents seizures by increasing GSH levels, which represents a crucial endogenous antioxidant that plays a key role in counteracting neuroinflammation and gut microbiota dysfunction. Furthermore, due to their antioxidant and anti-inflammatory properties, plant extract derivatives may be new agents that could reduce neuroinflammation in seizures, affecting the gut–brain axis (GBA) through the intestinal microbiota. In conclusion, data suggest that further clinical studies are needed to explore how the GM impacts epilepsy, and how specific nutraceuticals might offer probiotic benefits. Thus, a combined effect of nutraceuticals and functional food might be appealing, potentially resulting in a more beneficial therapeutic outcome.

3 August 2026 in Nutraceuticals
Verified
Journal Article
Open access
PDF file
CACarmen Altomare
Carmen Altomare
MSMaria Serra
Maria Serra
DDDenise Maria Dardano
Denise Maria Dardano
SUSara Ussia
Sara Ussia
GRGiovanna Ritorto
Giovanna Ritorto
RMRoberta Macrì
Roberta Macrì
Background: The Mediterranean Diet (MedDiet) is a global benchmark for the prevention of cardiometabolic diseases and healthy aging, with Olea europaea L. (O. europaea L.) and Citrus bergamia Risso et Poiteau (bergamot) serving as primary sources of bioactive molecules such as phenols, in particular flavonoids. Recent evidence highlights a paradigm shift from traditional agricultural yield toward a precision-nutrition model, in which the health-promoting potential of these species is increasingly recognized to arise from the interplay between genetic background and environmental factors. Objectives This review summarised current evidence on how genetic variability drives the metabolic fingerprints of olive and bergamot, exploring the integration of genomic, transcriptomic, and metabolomic data to identify cultivars with superior nutraceutical value. Results: Evidence suggests that phytochemical profiles of O. europaea L. and Citrus species, including bergamot, are shaped by the interaction between genetic background and environmental conditions, with genotype contributing significantly to metabolic variability. Specific O. europaea L. and Citrus genotypes display distinct metabolic fingerprints characterized by different bioactive compound profiles, potentially underlying variations in antioxidant, cardioprotective, lipid-lowering, and anti-inflammatory properties. Conclusions: The integration of high-resolution genotyping and metabolic profiling supports the selection of superior genotypes for standardized, evidence-based nutraceuticals. Future advances in precision breeding are expected to further enhance the health-promoting traits of these Mediterranean species.

Verified
Journal Article
Open access
PDF file
SUSara Ussia
Sara Ussia
GRGiovanna Ritorto
Giovanna Ritorto
RMRoberta Macrì
Roberta Macrì
MSMaria Serra
Maria Serra
ATAnnamaria Tavernese
Annamaria Tavernese
RMRocco Mollace
Rocco Mollace
Eicosanoids and their receptors act as key regulators of inflammation, calcium homeostasis, mitochondrial function, and cardiomyocyte survival, thereby contributing to the onset and progression of cardiac dysfunction. This review aims to summarize the evidence to underscore the pivotal role of eicosanoids and their receptors in the pathophysiology of cardiomyopathy, analysing the potential protective activity of traditional and natural compounds to counteract cardiovascular disease onset and progression. Among eicosanoid receptors, prostaglandin E2 receptor 3 (EP3), prostaglandin E2 receptor 4 (EP4), chemoattractant receptor expressed on type 2 helper T cells (CRTH2), and thromboxane prostanoid (TP) emerge as critical modulators with distinct and often opposing effects on cardiac physiology. While EP3 and CRTH2 are predominantly associated with detrimental outcomes such as impaired contractility and enhanced apoptosis, EP4 signalling consistently demonstrates cardioprotective properties, including improved calcium handling and preservation of mitochondrial integrity. These findings highlight the therapeutic potential of selectively targeting eicosanoid receptor pathways to mitigate cardiac remodelling and dysfunction. In parallel, increasing attention has been directed toward natural bioactive compounds as complementary strategies for cardioprotection. Polyphenols, flavonoids, carotenoids, and other nutraceuticals exert beneficial effects through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms, often intersecting with eicosanoid signalling pathways. Their ability to modulate oxidative stress and inflammatory responses suggests a promising role in preventing or attenuating cardiomyopathy, particularly in metabolic and drug-induced contexts. Future research should focus on well-designed clinical trials, a deeper characterization of receptor-specific signalling networks, and the development of targeted therapies that combine pharmacological and nutraceutical approaches. Overall, a better understanding of eicosanoid-mediated mechanisms may open new ways for cardiomyopathy prevention and treatment, ultimately improving patient outcomes and reducing the burden of cardiovascular disease.

Verified
Journal Article
Open access
PDF file
GRGiovanna Ritorto
Giovanna Ritorto
SUSara Ussia
Sara Ussia
RMRoberta Macrì
Roberta Macrì
MSMaria Serra
Maria Serra
ATAnnamaria Tavernese
Annamaria Tavernese
RMRocco Mollace
Rocco Mollace
Vascular endothelium balances antithrombotic and anti-inflammatory activity to control blood vessel tone under physiological conditions. However, endothelial dysfunction impairs these processes, causing a state that promotes clotting and inflammation. Eicosanoids are a major class of bioactive lipid mediators crucial for modulating endothelial and platelet function. Research has highlighted the roles of eicosanoids in vascular diseases, showing pro-inflammatory, prothrombotic, and protective activities. Specifically, prostaglandin E2 (PGE2) is crucial because of its major role in atherosclerosis development and progression, acting via EP receptors involved in forming, maintaining, and stabilizing atherosclerotic lesions, thereby making PGE2-EP signalling a specific target for treating cardiovascular diseases. This review will explore the evidence on eicosanoids and the role of their receptor modulation in platelet and vascular dysfunction in atherothrombosis. The studies included in this scoping review were retrieved from PubMed, Web of Science, Cochrane, and Scopus in accordance with the Preferred Reporting Items for Scoping Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) statement and the Population Intervention Comparison Outcome Population (PICO) framework. Eight clinical studies were found, which highlighted the crucial role of eicosanoids, like prostaglandins and their receptors, in endothelial and platelet dysfunction, and also how pharmacological mechanisms affect atherothrombosis. A new therapeutic approach for cardiovascular dysfunction is indicated by the recent findings, specifically against atherothrombosis, focusing on eicosanoids, their receptors, and processes like oxidative stress. Despite this evidence, there is a lack of comprehensive research results from scientific databases; therefore, further in vitro, in vivo, and clinical studies should be promoted to validate the preliminary results.

12 October 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
DDDenise Maria Dardano
Denise Maria Dardano
RMRoberta Macrì
Roberta Macrì
MSMaria Serra
Maria Serra
CACarmen Altomare
Carmen Altomare
GRGiovanna Ritorto
Giovanna Ritorto
VMVincenzo Mollace
Vincenzo Mollace
Curcumin, a natural polyphenol derived from Curcuma longa, exhibits multi-targeted anti-inflammatory, antioxidant, and neuroprotective activities. This review aims to evaluate its extraction methodologies, synthetic pathways, and neuroprotective potential across preclinical and clinical paradigms, while addressing bioavailability barriers and commercial adulteration. In cellular models (BV-2, U87), curcumin inhibits TLR4/MyD88/NF-κB and NLRP3 inflammasome signaling, resulting in the downregulation of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and enzymes (COX-2, iNOS), while simultaneously activating Nrf2/ARE antioxidant pathways. Moreover, it facilitates the polarization of neuroprotective M2 microglia. In animal models of ischemic stroke, traumatic brain injury, and Parkinson’s disease, curcumin reduces neuroinflammation, protects dopaminergic neurons, and maintains the integrity of the blood–brain barrier. Advanced nanocarriers such as PLGA nanoparticles, exosomes, and lipid complexes bypass rapid hepatic metabolism, thereby increasing brain bioavailability. Clinical data demonstrate that bioavailable formulations (Theracurmin, Longvida, CurQfen) could improve memory function and reduce cerebral amyloid and tau deposits in subjects without dementia and with mild cognitive impairment. Conversely, the use of unformulated curcumin results in inconsistent findings in trials for Alzheimer’s and Parkinson’s diseases owing to its poor systemic absorption. In conclusion, Curcumin might represent a promising multitarget neuroprotective agent; however, addressing pharmacokinetic limitations via bioavailable delivery systems and implementing rigorous quality control to prevent commercial adulteration are essential for effective clinical application.